Clinical Trials Logo

Salivary Cancer clinical trials

View clinical trials related to Salivary Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT02749903 Active, not recruiting - Salivary Cancer Clinical Trials

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Start date: June 2016
Phase: Phase 2
Study type: Interventional

This study will test any good and bad effects of the study drug called enzalutamide. Enzalutamide could shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size, in at least 1 out of 5 patients. Enzalutamide is not FDA approved to treat salivary gland cancer, but it has already been FDA-approved to treat other cancers.

NCT ID: NCT02628067 Recruiting - Cervical Cancer Clinical Trials

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Start date: December 18, 2015
Phase: Phase 2
Study type: Interventional

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

NCT ID: NCT02091141 Completed - Neoplasms Clinical Trials

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Start date: April 14, 2014
Phase: Phase 2
Study type: Interventional

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.